Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by Wall Street Zen
by Renee Jackson · The Cerbat GemRegeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.
Other equities research analysts have also recently issued reports about the company. Sanford C. Bernstein decreased their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Oppenheimer reiterated an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Finally, Wells Fargo & Company upped their price target on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $811.96.
Get Our Latest Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Stock Performance
Shares of REGN stock opened at $748.87 on Friday. The company’s fifty day simple moving average is $767.42 and its two-hundred day simple moving average is $721.06. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $821.11. The stock has a market capitalization of $79.17 billion, a price-to-earnings ratio of 18.02, a PEG ratio of 1.99 and a beta of 0.40.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the firm posted $12.07 EPS. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.
Insider Buying and Selling at Regeneron Pharmaceuticals
In other news, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,774 shares of company stock worth $2,942,738 over the last ninety days. Insiders own 7.02% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Insigneo Advisory Services LLC grew its holdings in shares of Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares during the last quarter. Guardian Wealth Advisors LLC NC grew its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 14 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in shares of Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 15 shares during the last quarter. MCF Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the last quarter. Finally, Rexford Capital Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 5.5% in the fourth quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 15 shares during the last quarter. 83.31% of the stock is owned by institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.